Secretion by tumor cells of circulating bone-resorbing factors may frequently underlie the hypercalcemia that occurs in patients with malignancy. Efforts to identify the responsible mediators have been hampered by a lack of available human tumor cell systems suitable for study of the pathogenesis of the humoral hypercalcemia syndrome. We have established a transitionalcell carcinoma (TCC) line in vitro from a patient with humoral hypercalcemia. These cells are tumorigenic and cause hypercalcemia in athymic nude mice. Culture medium conditioned by TCC cells contains potent bone-resorbing activity in vitro, the physical and biological properties of which are similar to those of bone-resorbing activity present in the original patient's urine. The bone-resorbing activity of the TCC factor is accompanied by increased prostaglandin release from bone and is blocked by indomethacin and calcitonin. The TCC-derived bone-resorbing activity coelutes with prostaglandin-stimulating activity during gel filtration with an approximate molecular weight of 15,000. This activity is nondialyzable, stable to concentrated urea and reducing agents, and destroyed by boiling. The TCC factor does not increase cyclic AMP production in bone or kidney bioassays and does not exhibit transforming growth factor activity. We conclude that a unique macromolecular factor released by TCC cells causes bone resorption by a mechanism dependent upon stimulation of bone cell cyclooxygenase, and that this factor is the probable cause of the hypercalcemia in vivo. The TCC cell line provides a new model for study of the human humoral hypercalcemia syndrome.
Introduction
Hypercalcemia occurs frequently in advanced malignancies and often severely compromises management ofthe underlying neoplasm (1) (2) (3) . Accelerated net bone resorption is believed to be the source of the hypercalcemia in such patients (1, 4, 5) , although understanding of the mechanisms whereby malignant cells alter the functions of normal bone cells remains incomplete. Direct osteolysis by tumor cells metastatic to bone may occur (6) . Often, however, circulating tumor-derived bone-resorbing Receivedfor publication 4 April 1985. factors appear to cause osteolysis, most clearly so in those patients whose hypercalcemia occurs in the absence of skeletal metastases (7) . The pathogenesis of this humoral hypercalcemia syndrome appears to be heterogeneous. Secretion by tumor cells ofa variety of bone-resorbing factors has been postulated, including parathyroid hormone (PTH)' (8) (9) (10) , prostaglandins (11) (12) (13) , osteoclast-activating factor and other leukocyte products (14) (15) (16) (17) , transforming growth factors (1, 18, 19) , and agents with PTHlike actions on bone and kidney (20) (21) (22) .
Efforts to purify and characterize unknown bone-resorbing factors derived from human tumors have been impeded by the relative insensitivity of available in vitro bone resorption bioassays and, more importantly, the limited availability of human tumor tissue as a source of active factors. We have recently established a continuous tumor cell line from a patient with transitional-cell carcinoma (TCC) and humoral hypercalcemia.
These tumor cells cause hypercalcemia when implanted in athymic nude mice and release a potent bone-resorbing factor in vitro that exhibits properties distinguishing it from agents previously implicated in the genesis of the humoral hypercalcemia of malignancy syndrome. The studies reported here provide the basis for a new model of human hypercalcemia of malignancy.
Methods

Clinical summary
The patient was a 54-year-old Caucasian woman who was found to be hypercalcemic (12.6 mg/100 ml) when admitted for a hypertensive lacunar stroke in February 1983 . She had a history of alcoholism and was taking hydrochlorothiazide for mild hypertension. In 1981, serum calcium and phosphorus had been noted to be 10.6 and 1.7 mg/100 ml, respectively. Evaluation ofthe hypercalcemia revealed an undetectable plasma amino-terminal immunoreactive PTH (iPTH) (<8 pg/ml), low serum 1,25(OH)2D (15 pg/ml), elevated carcinoembryonic antigen (45 ng/ml), and urine cytology positive for TCC. A 99'Tc diphosphonate bone scan showed a generalized increase in skeletal uptake but no focal lesions. 24-h urinary calcium excretion was 160 mg. The following studies were normal: blood urea nitrogen, creatinine, alkaline phosphatase, urinary Bence-Jones protein, serum immunoelectrophoresis, chest x-ray, and liver-spleen scan. Serum calcium and phosphorus ranged between 12.6 and 13.7 mg/100 ml and between 3.3 and 5.7 mg/100 ml, respectively, and creatinine gradually rose to 2.5 mg/100 ml. Hypercalcemia and azotemia failed to respond to discontinuation of the diuretic, intravenous hydration, or oral orthophosphate but were successfully managed with mithramycin. Diffuse retroperitoneal node involvement was found at laparotomy, and a portion ofan excised lymph node was used to establish the cell line reported here.
Tumor burden and hypercalcemia responded to repetitive courses of intravenous methotrexate, but urinary frequency ultimately prompted readmission in September 1983 , when cystoscopy showed the bladder to be filled with tumor. Renal function had remained normal since her previous discharge, however, and urine cultures were negative. During this admission, serum calcium and phosphorus ranged between 9.7 and 12.4 mg/100 ml and between 2.1 and 2.8 mg/100 ml, respectively, a third bone scan was unchanged, and a total of eight 24-h urine collections were performed for measurement of urinary cyclic AMP excretion, the mean±standard error of the mean of which was 4.8±0.8 nmol/100 ml glomerular filtrate. These and others were also concentrated for study of urinary bone-resorbing activity, as described below. Over the next 3 mo, further progression of locally metastatic disease occurred despite chemotherapy, renal failure resulting from ureteral obstruction ultimately supervened, and the patient expired. Permission for an autopsy was not granted.
Culture oftumor cells
Tumor tissue obtained at surgery was minced to 1-2-mm fragments in 100-mm plastic petri dishes containing 15 ml of Dulbecco's modified Eagle's medium (DME) supplemented with 5% fetal bovine serum ("5% DME"). Explants (10-20 fragments per dish) were incubated at 370C in a humidified atmosphere of 5% CO2 in air with medium changes once or twice each week. Homogeneous populations of polygonal tumor cells grew out from these explants and were maintained in 5% DME with serial subculturing by trypsinization at 3-4-wk intervals. 3 d after feeding confluent monolayers of these tumor cells in 150-cm2 flasks with 5% DME, the medium was discarded and replaced with 25 ml of DME containing 0.5% horse serum. The conditioned medium was then harvested after 2 d and the procedure was repeated once before returning the cells to 5% DME. The conditioned medium was centrifuged at 2,000 g for 15 min and stored at -20'C until further processing.
Tumor growth in athymic nude mice Freshly trypsinized tumor cells, washed once with 5% DME, were resuspended in serum-free DME at 2-4 X 106 cells/ml and administered subcutaneously (0.5 ml per animal) to athymic nude mice ( Ham's F-12 medium with 5% fetal bovine serum and 1% kanamycin (Gibco) in 16-mm wells. Cells were incubated first at 37°C in air for 30 min in 0.5 ml of PAG buffer (phosphate-buffered saline with 2 mg/ml ofglucose and 4 mg/ml of heat-inactivated bovine albumin), this buffer was discarded, and test agents were then added in 0.2 ml of PAGI buffer (PAG with I mM isobutylmethylxanthine). Incubations were terminated after 10 min by addition of cold methanol (I ml/well), the cell layers were extracted twice more with methanol, the combined extracts were evaporated by vacuum centrifugation, and the dried extracts were redissolved in acetate buffer for measurement of cyclic AMP by a specific radioimmunoassay (New England Nuclear). Calvarial bones. Neonatal mouse calvaria were obtained as above and incubated at 37°C in PAG buffer for up to 1 h before transfer of individual bones to siliconized (Sigmacote, Sigma Chemical Co.) glass tubes containing test agents in 0.25 ml of PAGI buffer. Reactions were conducted for 10 min at 37°C and terminated by addition of I ml of cold methanol. Bones were sonicated for 30 min at room temperature, the methanol extraction was repeated twice, and the combined extracts were then evaporated and processed for cyclic AMP radioimmunoassay as described above. Significant stimulation of calvarial cyclic AMP was usually evident at concentrations of bPTH(1-34) between 0.5 and 1.0 x 10-9 M. In some experiments, cyclic AMP was measured directly in aliquots of medium obtained at 72 h from the bone resorption bioassay.
Prostaglandin synthesis
Prostaglandin E2 (PGE2) in medium from cultures of mouse calvaria was determined by specific radioimmunoassay (New England Nuclear) after appropriate dilution of the media in assay buffer. Control culture media at these dilutions were found not to interfere with measurement of added standard PGE2 in this assay.
Epidermal (EGF) and transforming (TGF) growth factor activities Binding of 251I-labeled murine EGF to human A43 1 cells was studied as described by DeLarco et al. (26) except that cells, grown in 5% DME, were plated at 1.25 X 10' cells/cm2 in 16-mm plastic wells 24 h before study. Radioiodinated murine EGF (170 gCilsg, Collaborative Research Co.) was added (30,000 dpm/0.35 ml) to wells containing 0.5 ml of test samples or standard EGF (Biomedical Technologies Inc., Cambridge, MA), and specific binding was determined after 60 min at 20'C.
Induction of anchorage-independent growth of non-neoplastic rat cells was assessed essentially as described by Roberts et al. (27) . Briefly, normal rat kidney cells (clone 49F) were plated at a density of 500 cells per microtiter well in 0.2 ml of DME containing 0.3% agarose and 10% calf serum (Flow Laboratories, Inc., McLean, VA) with or without EGF (5 ng/ml, Collaborative Research Co., Lexington, MA). Cells were incubated for 7 d in a humidified atmosphere of 10% CO2 in air and then stained with 2-(p-iodophenyl)-34p-nitrophenyl)-5-phenyl tetrazolium chloride (0.5 mg/ml) for enumeration of colonies containing >20 cells.
Purified ,-TGF was prepared by acid/ethanol extraction ofnormal human platelets and subsequent chromatography on Bio-Gel P-60 (Bio-Rad Laboratories, Richmond, CA) as previously described (28) . This purified factor elicited a half-maximal increase in colony formation at a protein concentration of 25 ng/ml.
Column chromatography
Concentrates (5 ml) were applied to 2.5 X 90-cm columns of Ultrogel AcA 44 (LKB Co., Gaithersburg, MD) and eluted by ascending flow with 0.1 N acetic acid in 50 mM ammonium acetate, pH 4.1, at a flow rate of 22 ml/h. Fractions (4 ml) were collected, optical density at 280 nm was determined, and selected fractions were lyophilized and redissolved in medium for direct bioassay of bone-resorbing activity.
Other procedures
Immunoreactive PTH was measured in plasma, concentrated cell medium, or urine using chicken antiserum CK-67, which exhibits specificity for the amino-terminal region ofthe PTH sequence (29) . The sensitivity of the PTH immunoassay for human PTH(1-34) was -1-2 pg/tube. Serum 1,25(OH)2D was measured by specific radioimmunoassay in the laboratory of Dr. Thomas Clemens at the Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, where normal levels were 20-65 pg/ml. Cyclic AMP was measured in appropriately diluted (1:100 to 1:1000) urine by a commercial radioimmunoassay (New England Nuclear) that was highly specific for cyclic AMP. Serum and urinary creatinine were measured in the hospital's Clinical Chemistry Laboratory.
Values for total urinary cyclic AMP (nmol/100 ml ofglomerular filtrate) measured by these techniques in normal subjects (3.1±0.4, n = 6) and in patients with primary hyperparathyroidism (9.9±0.8, n = 7), hypercalcemia owing to solid tumors not metastatic to bone (7.0±1.2, n = 12), and hypercalcemia owing to hematologic malignancy (3.1±1.4, n = 3) were in agreement with data provided by the supplier ofthe cyclic AMP kits and with results previously published by others (30, 31) .
For organic extraction, aliquots of medium and urine concentrates were diluted to I ml with saline, acidified to pH 3.5 with glacial acetic acid, and extracted three times with 3 vol of ethyl acetate. In control experiments, this procedure resulted in over 98% extraction of[3H]PGE2 added as an indicator of the efficiency of the separation. The combined ethyl acetate extracts were evaporated to dryness under a stream of nitrogen and redissolved in medium for bioassay. The aqueous phases were dialyzed against 140 mM NaCl, 1 mM sodium phosphate, pH 7.4, and diluted with medium prior to bioassay.
Results
Cultured tumor cells from this patient ("TCC cells") were tumorigenic when administered subcutaneously to athymic nude mice. Moreover, the majority oftumor-beaning mice developed hypercalcemia (Fig. 1 ) by 8 wk in the absence ofbony metastases either at autopsy or by radionuclide bone scanning (four mice).
Renal function remained normal in the tumor-bearing animals.
Concentrates of both the patient's urine and of conditioned medium from her cultured tumor cells contained potent boneresorbing activity when tested in the mouse calvarial resorption assay (Fig. 2) . Moreover, the biologic and chemical properties of the activity in conditioned medium and the patient's urine were similar by a variety of independent criteria. Thus, in both cases, the activity was nondialyzable and was not destroyed by exposure to denaturing (8 M urea) or reducing (65 mM dithiothreitol) agents (Table I) . Activity was stable upon heating to 560C for 45 min but was lost upon boiling for 10 min. No PTH immunoreactivity was detectable in either urine or medium concentrates at dilutions active in the resorption bioassay, and levels of PGE2 were <100 pM, which is 100-fold lower than the detection limit of the resorption assay for PGE2 (Fig. 2) . The possibility that other lipid-soluble substances (other prostaglandins, vitamin D metabolites, vitamin A) might be responsible for the bone-resorbing activity in TCC medium or urine concentrates was addressed by extracting these concentrates with ethyl acetate and then testing the organic extracts and residual aqueous phases for bone-resorbing activity. As shown in Table  I , all of the bone-resorbing activity in both preparations remained in the aqueous phases, and none was found in the corresponding organic extracts. In addition, resorption induced by both concentrates was almost completely blocked by calcitonin, and neither preparation caused increased release of radiocalcium from bones previously devitalized by repetitive freeze-thawing (Table I) . Gel filtration chromatography of both patient urine and TCC medium concentrates demonstrated a single major peak of bone-resorbing activity that eluted with an apparent molecular weight of -15,000 (Fig. 3) .
Both urine-and cell-derived resorbing activities were associated with increased release of immunoreactive PGE2 by the calvarial bones, and, moreover, in both cases the bone-resorbing activity was inhibited by addition of indomethacin to the bone resorption bioassay (Table II) . By contrast, PTH also increased PGE2 release from these bones (Table II) , but the increased resorption induced by this hormone was unaffected by indomethacin, despite virtually complete blockade of PGE2 release by the drug. The possibility that bone-resorbing and prostaglandinstimulating activities in the TCC medium were properties ofthe same molecule was further supported by the demonstration of coelution of these two activities during gel-filtration chromatography ( Fig. 3 A and B) .
Concentrated urine and cell medium were tested for evidence of PTH-like adenylate cyclase-stimulating activity using several in vitro bioassays. When cyclic AMP was measured in the medium ofcultured calvarial bones undergoing resorption 3 d after addition of maximal doses of TCC medium, no evidence of delayed stimulation of cyclic AMP production was observed, whereas increases in medium cyclic AMP were seen when bones were treated with doses of PGE2 causing comparable bone resorption (see legend to Table III) . At doses causing maximal activity in the bone resorption assay, neither TCC medium nor patient urine concentrate increased adenylate cyclase activity acutely in isolated canine renal membranes (Fig. 4) PTH elicited the expected large increments in cyclic AMP (Table  III) . Because slight inhibition of basal renal membrane adenylate cyclase occurred at higher doses of TCC medium (Fig. 4) , we studied the response of these membranes to bPTH in the presence and absence of maximal levels of TCC medium concentrate (10 Ml/ml). As shown in Fig. 4 , the adenylate cyclase response to bPTH(1-34) was inhibited slightly by added crude TCC medium concentrate. Comparable results were observed with the osteosarcoma cells (Table III) . This apparently nonspecific inhibition seems inadequate to account for the complete absence of adenylate cyclase responsiveness to TCC medium alone, however.
Active TCC medium concentrates were also tested for the presence of constituents that might bind to receptors for EGF (Fig. 5) . Although binding was reduced slightly below that of control wells in the presence of TCC concentrate, this was also true of control medium concentrate, and no dose-response relation was evident in either case. These data indicate that TCC medium concentrates, at dilutions (1:50 or more) maximally active in the bone resorption assay, must contain <0.1 ng/ml of EGF-equivalent receptor binding activity. By contrast, EGF elicits maximal resorption of mouse calvaria in vitro only at doses higher than 1 ng/ml (32) , and then only in the presence of fetal bovine or calf serum (not used in our studies). The presence of TGF activity in medium concentrates was also sought by testing for induction of anchorage-independent growth of normal rat kidney fibroblasts in soft agar in the presence and absence of EGF. At doses as high as 100 gl/ml, however, TCCcell medium concentrates failed to stimulate significantly any growth of fibroblast colonies after 7 d, whereas purified plateletderived f3-TGF elicited up to 200 colonies per well (Table IV) .
The response to platelet ,B-TGF was not inhibited in the presence of 20 ,ul/ml of TCC medium (not shown).
Discussion
Urothelial cancers are frequently associated with humoral hypercalcemia (3) , and the patient reported here exhibited the characteristic clinical features of the humoral hypercalcemia syndrome (1, 7) . Thus, hypercalcemia occurred in the absence of radiographically demonstrable bone metastases, serum phosphorus and 1,25(OH)2D were low, and plasma iPTH was undetectable, in spite of which urinary cyclic AMP excretion was not suppressed. The severity of the hypercalcemia fluctuated with treatment of the patient's underlying malignancy, and therapy with glucocorticoids and orthophosphate were not clearly successful in relieving the hypercalcemia. The virtual replacement of the patient's bladder by invasive tumor provided a unique opportunity to collect directly the products of tumorcell secretion in vivo. Moreover, the establishment ofthe patient's tumor cells as a continuous cell line in vitro permitted direct study ofthe nature ofthe cellular product(s) potentially responsible for the humoral hypercalcemia. The similarity, both physicochemical and biologic, of the bone-resorbing factors identified in concentrates ofthis patient's urine and of culture medium conditioned by exposure to her tumor cells in vitro suggests that these TCC cells have continued to release the same active factor in vitro as had been produced previously in vivo. Moreover, the occurrence of humoral hypercalcemia in athymic nude mice bearing TCC tumors strongly supports the hypothesis that the bone-resorbing factor released by these cells in vitro causes hypercalcemia in vivo and was likely responsible for the patient's hypercalcemia. Nevertheless, direct proof of this hypothesis awaits the availability of highly purified bone-resorbing factor.
The bone-resorbing factor released by TCC cells exhibits properties that distinguish it from several other factors previously ,gl/ml), these preparations of control and TCC medium concentrates elicited 25±3 and 51±3% 45Ca release, respectively (assay control, 25±2%).
thesized by calvarial bones in response to the TCC factor. These are the same prostaglandins observed by others in cultures of mouse bones resorbing in response to phorbol esters or EGF (32, 36) . Because of the heterogeneity of cell populations within the calvarial tissue, the precise cellular origin of the prostaglandins measured in the medium of bones treated with TCC factor remains unknown. Moreover, the mechanism(s) whereby increased prostaglandin release initiates accelerated bone resorption induced by this material is also unclear. It is ofinterest that PTH also causes increased medium PGE2 in these bone cultures (Table  II) but that indomethacin, although it blocks the increment in PGE2, fails to inhibit the resorption induced by this hormone. These observations indicate that the nature of the biologic consequences of increased prostaglandin production in bone may depend upon the particular agent stimulating this production, the identity of the cells responsible for the augmented prostaglandin synthesis, or, possibly, the pattern of arachidonate metabolites produced. The potent inhibitory effect of calcitonin seen in our studies suggests that increased osteoclastic activity underlies the resorptive effects of the factor, although the synthesis of prostaglandins and, possibly, ofa prostaglandin-dependent regulator of osteoclast activity might occur in adjacent osteoblasts in the calvarial tissue (37) . The increased release of prostaglandins by bone in response to this or similar factors secreted by tumors in patients with humoral hypercalcemia could account for the elevated levels of plasma prostaglandins often seen in such patients ( 13) , the occasional response of humoral hypercalcemia to indomethacin or aspirin (1, 11, 13) , and the observation that tumor prostaglandin content often correlates poorly with hypercalcemia (38) . The involvement of prostaglandins in the resorptive response of mouse calvaria to TCC factor is analogous to the effects of some bone-resorbing growth factors, including EGF and plateletderived growth factor, in this tissue (32, 39) . This is of particular interest in light ofthe hypothesis of Mundy et al. (1, 18, 19) (20) (21) (22) . Analogous observations have been made using a highly sensitive renal cytochemical bioassay (20) . It has thus been proposed that such factors, although immunochemically and chromatographically distinct from PTH, might nevertheless interact with PTH receptors in bone and kidney to initiate increased bone resorption and decreased renal tubular phosphate reabsorption by cyclic AMP-mediated mechanisms (20) . Such effects might account for hypercalcemia, hypophosphatemia, and high nephrogenous cyclic AMP excretion seen in humoral hypercalcemia, even though other common features of the syndrome, including low levels of serum 1 ,25(OH)2D, elevated fractional excretion of calcium, and histologically apparent uncoupling of bone resorption and formation rates (5), would still not be readily explained. In light of these reports, we carefully examined the possibility that such a PTH-like factor might be present in our TCC medium or urine concentrates. Extensive studies of the possible effects of these concentrates on cyclic AMP production in a variety of PTH-responsive bioassays, including the calvarial bone cultures used for the resorption measurements, failed to reveal any evidence of such a factor, however. This was true even at doses well above those that elicit maximal activity in the bone resorption bioassay. The absence of adenylate cyclase-stimulating activity appears not to be due to the presence in these concentrates of nonspecific inhibitors of the bioassay. These observations clearly indicate that the TCC factor induces bone resorption in vitro by a mechanism not involving activation ofPTH-receptorlinked adenylate cyclase. The source ofthe abundant cyclic AMP present in our patient's urine is not known with certainty. Although her total urinary cyclic AMP excretion (4.8 nmol/100 ml glomerular filtrate) is such that we cannot unambiguously classify this patient into either the high-or low-cyclic AMP groups proposed by Stewart et al. (7), this amount of urinary cyclic AMP seems inappropriate in the setting of persistently undetectable serum iPTH. It is possible that the tumor cells in her urinary tract may have released large amounts of cyclic AMP directly into the urine, although we have not observed high concentrations of cyclic AMP in fresh medium from the TCC cell cultures. Because plasma cyclic AMP was not measured, it is possible that much of the cyclic AMP present in the patient's urine derived from glomerular filtration. Finally, others have reported elevations of nephrogenous cyclic AMP in normocalcemic cancer patients (31, 41) , which suggests that this abnormality may be a general feature of some malignancies that is unrelated to coexisting abnormalities in calcium metabolism.
In summary, we have identified a potent macromolecular bone-resorbing factor released in vitro by a tumor cell line established from a patient with humoral hypercalcemia of malignancy. This cell line, which is tumorigenic and causes humoral hypercalcemia in athymic nude mice, provides a new experimental model for study of the human humoral hypercalcemia syndrome. The factor released by these cells in vitro is physically and biologically similar to activity recovered from the patient's urine, which had been in direct contact with a large mass of tumor tissue. Our studies suggest that this factor is different from others previously implicated as causes of the humoral hypercalcemia syndrome and that its effects on bone resorption are mediated by an increase in prostaglandin synthesis in bone cells. Purification and further study of the mechanism of action of this factor, both in vivo and in vitro, should lead to better understanding of the pathogenesis of humoral hypercalcemia of malignancy.
